Medvolt is redefining early-stage drug discovery by making advanced generative AI and physics-based simulation technologies accessible to a broader spectrum of researchers. At the heart of this transformation lies its flagship platform, MedGraph®, which powers pharmaceutical R&D through a suite of modular, AI-driven tools. These include Rubie™ for drug repurposing, Topaaz for novel chemical entity development, EDGE for rapid insight generation, and a dedicated peptide therapeutics module. Together, these components streamline workflows, cut development costs, and significantly boost the probability of success.
Driving this innovation is a robust technological core that seamlessly integrates state-of-the-art AI—including natural language processing, generative modeling, and reinforcement learning—with curated biomedical datasets. These datasets are harmonized through Data Ocean and an ontology-based Knowledge Graph, enabling intelligent, data-rich decision-making. Medvolt’s cloud-native, scalable infrastructure ensures secure, on-demand access across the pharmaceutical and biotech landscape, empowering teams globally to harness its capabilities without barriers.
Beyond platform excellence, Medvolt delivers end-to-end solutions such as Data as a Product (DaaP), AI-accelerated discovery for both small and large molecules, and customizable knowledge engines tailored to specific R&D needs. The leadership team reflects this forward-thinking ethos—Dr. Madhura Vipra, a translational biomedical researcher and AI product strategist, and Ritvik Vipra, an IIT Roorkee alumnus and accomplished ML engineer, bring together scientific rigor and technical depth.
In 2025, Medvolt’s inclusion in the NVIDIA Inception Program further strengthened its AI capabilities and global visibility. Additionally, its participation in the PRIP Industry Dialogue 2025 underscored its advocacy for progressive policy reforms in India’s Pharma and MedTech sectors.
Medvolt stands at the vanguard of a new era—where drug discovery becomes intelligent, agile, and cost-effective.
In an exclusive conversation with The Interview World at Startup Mahakumbh, Ritvik Vipra, Co-founder of Medvolt, delves into the platform’s groundbreaking AI innovations, reveals the core technologies driving change, discusses how Medvolt is poised to disrupt the pharmaceutical industry, and outlines its strategic roadmap and key clients.
Here are the highlights from that insightful exchange.
Q: What are some of the most significant innovations Medvolt has introduced to transform the pharmaceutical sector, and how are they addressing current industry challenges?
A: Medvolt operates at the cutting edge of data, life sciences, and artificial intelligence to revolutionize the preclinical phase of pharmaceutical R&D. This stage—often the most capital-intensive and time-consuming in drug discovery—demands numerous experimental iterations to validate outcomes.
However, here lies the fundamental challenge: while experimental validation remains indispensable, the sheer volume of iterations significantly inflates both time and cost. Medvolt addresses this bottleneck head-on.
By harnessing the power of AI and data-driven insights, the company streamlines experimental design, dramatically reducing the number of required iterations. In doing so, it preserves scientific rigor while accelerating timelines and cutting costs. In essence, Medvolt brings the pharmaceutical industry closer to its ‘holy grail’—faster, leaner, and more efficient drug discovery without compromising accuracy or efficacy.
Q: Can you walk us through the core technology powering your solution?
A: At MedVolt, we achieve this transformation through our proprietary technology platform that seamlessly integrates generative AI with advanced physics-based simulations. This powerful combination shifts a significant portion of experimental work into the computational realm—accurately and efficiently.
As a result, what once required 1,000 experimental iterations can now be accomplished in just 100. The outcome is clear: dramatically reduced time, significantly lower costs, and no compromise on precision.
Our platform is not theoretical—it’s fully developed, rigorously validated, and proven both internally and through external collaborations. Today, we offer this platform as a robust SaaS solution to clients across the pharmaceutical ecosystem. Simultaneously, we’ve taken the next strategic step by building our own pipeline of drug assets, further unlocking value through innovation and deep domain expertise.
Q: In what ways do you see your innovation disrupting the pharmaceutical industry?
A: As you can see, we approach this across several critical endpoints—each delivering transformative impact. From a time standpoint, processes that traditionally span 3 to 5 years are now completed within just 18 to 24 months. That’s a reduction of nearly 50%, and in some cases, even more.
However, the gains in cost-efficiency are even more dramatic. On the preclinical experimentation front, we achieve up to a 10x reduction in cost. This is made possible by replacing the traditional need for 1,000 experimental iterations with just 100—thanks to the power of our platform.
In essence, we’re not just accelerating timelines; we’re fundamentally redefining the economics of preclinical drug discovery.
Q: Which key clients or partners are currently leveraging your solutions, and what strategic plans do you have for scaling or expanding in the near future?
A: We primarily serve clients across the U.S. and European biotech and pharmaceutical ecosystems, with a growing presence in India. Our customer base spans the full spectrum—from early-stage biotech startups to mid-sized firms, large pharmaceutical companies, and contract research organizations (CROs). In addition, several university research labs have also partnered with us, further expanding the impact of our platform across academia and industry.
